22.1 C
New York
Tuesday, May 17, 2022

Leap Therapeutics Inc. (LPTX) Stock Surges Following Successful Initial Data from DisTinGuish Clinical Trial

Leap Therapeutics Inc. (LPTX) stock prices were down by 2.67% as of the market closing on September 10th, 2021. This brought the price per share down to USD$1.46 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 28.08%, bringing it up to USD$1.87.

Success of Initial Data

September 13th, 2021 saw LPTX stock announce its plan to present initial data from its first-line cohort of the DisTinGuish study. The study is a Phase 2a clinical trial that is designed to evaluate the company’s anti-Dickkopf-1 (DKK1) antibody, DKN-01. The treatment will be administered in combination with tislelizumab, BeiGene’s anti-PD-1 antibody and chemotherapy. The study enrolled patients with gastric or gastroesophageal junction cancer (G/GEJ). The findings are expected to be presented at the European Society for Medical Oncology Congress, which will be held virtually from September 16th-21st 2021.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Scope of LPTX Stocks Trial

LPTX stock has been encouraged by the highly promising initial data from the DisTinGuish study. DKN-01 in combination with tislelizumab and chemotherapy has been shown to have high response rates in first-line patients with gastric and gastroesophageal junction cancer. Patients with tumors that exhibit high levels of DKK1 expression showed the highest response rates. High levels of DKK1 expression have been associated with aggressive disease progression and poor prognosis. The findings suggest the importance of the biomarker in predicting response to therapy.

Collaboration with Beigene

The study is being conducted in two parts, one in the United States and the other in the Republic of Korea. Enrollment of Part A has been concluded with 25 first-line HER2-G/GEJ cancer patients. The patients’ tumors exhibit either high levels of DKK1 (DKK1-high) or low levels (DKK1-low). Part B of the study is expected to enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. LPTX stock is conducting the ongoing combination study as part of an exclusive option and license agreement with BeiGene. The agreement is set to facilitate the development, commercialization, and proliferation of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

Future Outlook for LPTX Stock

The company reported a promising quarter, consolidated by the positive outcome of the initial data from its DisTinGuish study. LPTX stock is keen to leverage the resources at its disposal to facilitate the speedy commercialization and proliferation of its proprietary treatment. Current and potential investors are hopeful that this will result in consistent and organic growth over the long term.

Related Videos

Latest news

Related news

Related Videos


Please enter your comment!
Please enter your name here